Biocon Limited
Aditya Birla Sun Life Mutual Fund bought 6,26,000 shares of Biocon for ₹25.04 Cr at ₹400.00 apiece in a block deal. This occurred as Mylan Inc. fully exited its 5.64% stake in Biocon through a block deal.
A leading biotechnology company engaged in the manufacture of innovative pharmaceutical products and research services across multiple therapeutic areas. Biocon specializes in biologics, biosimilars, and small molecule drugs, serving patients in oncology, immunology, and diabetes therapeutics globally. The company operates integrated manufacturing facilities and maintains a strong commitment to developing affordable healthcare solutions for patients in emerging markets worldwide.
Joint venture between Aditya Birla Capital and Sun Life Financial of Canada. Among India's top five AMCs with over Rs 6.5 lakh crore in AUM across 100+ schemes. MD and CEO A. Balasubramanian is one of the most outspoken fund industry voices in India. CIO Mahesh Patil oversees the equity book with a consistent large and multicap tilt.